A large US government order for a corona vaccine has breathed life into BioNTech shares. The value of the vaccine on the Nasdaq technology exchange rose by five percent on Thursday. Goldman Sachs analysts then reacted and raised their estimates for the Mainz-based biotech company. American investment bank Goldman Sachs raised the target price for …
Shares of BioNTech on Wednesday reached a new low for the year. However, it turned out to be a false signal. On Thursday, the paper could even grow significantly. In U.S. trading, the paper strengthened about seven percent to $ 132.29. A biotech company based in Mainz has also benefited from the good news about …
BioNTech: Oncology Channel – positive news from the EMA Read More »
Last weekend, mRNA specialist BioNTech announced that two customized omicron vaccine candidates had elicited a strong immune response in the test phase. Analysts at Bryan Garnier then took another hard look at the biotech stock and stood by their assessment. Investment house Bryan Garnier left BioNTech with a “buy” rating and a $296 price target …
BioNTech: Recommendation for purchase – SHAREHOLDER Read More »
The U.S. government has ordered another large-scale corona vaccine from the Mainz-based biotechnology company BioNTech and its pharmaceutical partner Pfizer for a planned reinforcement campaign in the fall. Namely, it is about at least 105 million doses and an agreed volume of over 3.2 billion dollars, according to the companies. Deliveries should begin in late …
